Overview

A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The study is a two period (8-10 days/period), incomplete cross-over in which successive cohorts of 9 subjects are randomized, in a 2:1 ratio, to 1 of 2 sequences, A and B. In each cohort, Sequence A, comprised of 6 subjects, receives ascending doses of ganaxolone during period 1 and ganaxolone (at the maximal dose attained in period 1) and ascending doses of placebo during period 2. Sequence B, comprised of 3 subjects, receives ascending doses of placebo during period 1 and receives the maximum dose of placebo and ascending doses of ganaxolone during period 2. The dosing level in each subsequent cohort will be based upon experience gained from previous cohorts.
Phase:
Phase 2
Details
Lead Sponsor:
Marinus Pharmaceuticals
Treatments:
Ganaxolone
Pregnanolone